Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | ROR1 | Q01973 | 6/20 | 0.56 |
| ▸ | ABL1 | P00519 | 12/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14705592 | 0.85 | CSF1R (0.55) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL29506341 | 0.83 | CSF1R (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL22580709 | 0.83 | CSF1R (0.61) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL15096062 | 0.83 | ROR1 (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL30010219 | 0.83 | CSF1R (0.72) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL17471714 | 0.82 | ABL1 (0.54) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL22243490 | 0.82 | CSF1R (0.66) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL29493472 | 0.82 | CSF1R (0.66) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL17471729 | 0.81 | CSF1R (0.56) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL17471718 | 0.81 | ABL1 (0.52) | CSF1RROR1ABL1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | CSF1R 1248/4885ROR1 1517/4885ABL1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.